Contribution to determining the antioxidant capacity of melatonin in orodispersible tablets - comparison with reference antioxidants.

Introduction: Melatonin is a hormone used in the treatment of diverse pathologies due to its ability to regulate numerous physiological processes related to biological rhythms and neuroendocrine function.

Material And Methods: This study examines whether or not the antioxidant capacities of melatonin are modified during the creation of fast disintegrating oral tablets (FDDTs) through direct compression in which different concentrations of the active substance (3, 5, 10 and 60 mg) and excipients are made. In addition, the antioxidant capacity of melatonin is compared with that of reference antioxidants such as vitamin C, Trolox, resveratrol, glutathione and nicotinamide adenine dinucleotide phosphate (NADPH).

Encapsulation in Cell Therapy: Methodologies, Materials, and Clinical Applications.

Background: The clinical application of cells and the development of new delivery systems have allowed significant advances in the field of cell therapy and encapsulation in recent years. The ability to combine cells and biocompatible matrices in the encapsulation of cells providing long-term delivery has provides new therapeutic alternatives in the development of new therapies.

Methods: A structured search of bibliographic databases was carried out to determine the entire methodology related to cell encapsulation with clinical application.

Mesenchymal Stem Cells as Therapeutics Agents: Quality and Environmental Regulatory Aspects.

Mesenchymal stem cells (MSCs) are one of the main stem cells that have been used for advanced therapies and regenerative medicine. To carry out the translational clinical application of MSCs, their manufacturing and administration in human must be controlled; therefore they should be considered as medicine: stem cell-based medicinal products (SCMPs). The development of MSCs as SCMPs represents complicated therapeutics due to their extreme complex nature and rigorous regulatory oversights.

Development of a cell-based medicinal product: regulatory structures in the European Union.

Introduction: New therapies with genes, tissues and cells have taken the emerging field for the treatment of many diseases. Advances on stem cell therapy research have led to international regulatory agencies to harmonize and regulate the development of new medicines with stem cells.

Sources Of Data: European Medicines Agency on September 15, 2012.

Multifunctional anticancer nanomedicine based on a magnetically responsive cyanoacrylate polymer.

The therapeutic effect of antitumor molecules (efficacy and safety) is severely limited by their poor pharmacokinetic characteristics. Recently, the use of colloids has been proposed for the delivery of anticancer drugs to tumor cells, thereby providing a significant advance toward new treatments with improved specificity. In this respect, magnetically responsive nanopolymers are probably one of the most promising materials.

[The future of new therapies in clinical medicine].

Advanced therapies provide a new concept of personalized medicament of autologous, allogeneic or xenogeneic origin, based on cells (cell therapy), genes (gene therapy) or tissues (tissue engineering), which, together with nanosystems, provide new advances in the diagnosis, prevention and treatment of diseases. The basis and different fields of action of cell therapy, gene therapy and nanomedicine are described in this review.

Chitosan nanoparticles as a new delivery system for the chemotherapy agent tegafur.

Background: Despite the very efficient antitumor activity of conventional chemotherapy, generally high doses of anticancer molecules must be administered to obtain the required therapeutic action, simultaneously leading to severe side effects. This is frequently a consequence of the development of multidrug resistance by cancer cells and of the poor pharmacokinetic profile of these agents.

Objective: In Order to improve the antitumor effect of tegafur and overcome their important drawbacks, we have investigated its incorporation into a drug nanoplatform based on the biodegradable polymer chitosan.

Iron/ethylcellulose (core/shell) nanoplatform loaded with 5-fluorouracil for cancer targeting.

Even though 5-fluorouracil has been demonstrated to display antitumor activity against a wide variety of cancers, high doses are needed to bring out the required therapeutic activity that could simultaneously lead to severe side effects. We hypothesized that the efficient delivery of 5-fluorouracil to tumors using a magnetic nanoplatform could reduce the dose required to obtain sufficient anticancer response. Thus, we have formulated a 5-fluorouracil-loaded magnetic nanomedicine consisting of a magnetic core (iron) and a biocompatible polymeric shell (ethylcellulose).

Formulation and physicochemical characterization of poly(epsilon-caprolactone) nanoparticles loaded with ftorafur and diclofenac sodium.

Even though conventional pharmacotherapy has been demonstrated to display very efficient activity against a wide variety of diseases, several active agents (e.g., anti-tumor drugs and non-steroidal anti-inflammatory drugs) are generally needed to be administered at high doses to elicit the required therapeutic action, simultaneously leading to severe side effects.

Vesicular lipidic systems, liposomes, PLO, and liposomes-PLO: characterization by electronic transmission microscopy.

Situations exist in which rapid administration of treatment, as well as maintenance of efficient concentrations for the longest possible time, turns out to be essential. In view of the previous treatment, the elaboration of liposomes, PLO (pluronic lecithin organogel), and the mixture of both is described, as well as their characterizations by electronic transmission microscopy, with the aim of finding out precisely the type of structure for both controlled release systems, its composition, size, homogeneity, and integrity. The period of study has been 90 days.

Tegafur loading and release properties of magnetite/poly(alkylcyanoacrylate) (core/shell) nanoparticles.

In this work, we describe a reproducible method to prepare polymeric colloidal nanospheres of poly(ethyl-2-cyanoacrylate), poly(butylcyanoacrylate), poly(hexylcyanoacrylate) and poly(octylcyanoacrylate) with a magnetite core, and loaded with the anticancer drug Tegafur. The method is based on the emulsion polymerization procedure, often used in the synthesis of poly(alkylcyanoacrylate) nanospheres for drug delivery. The heterogeneous structure of the particles confer them both magnetic-field responsiveness and potential applicability as drug carriers.